Sarepta’s big gene therapy expansion; Inside Iambic’s AI cycle; Vertex, Lilly unveil new diabetes data; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

Do you know a truly great private biotech out there with outstanding management, super science, ambitious and novel drug development plans, and the resources and backing needed to see the game out to pivotal data? If the answer is yes, consider nominating the company for this year’s Endpoints 11 — more details here.

Will Sarepta’s big gene therapy expansion set a precedent?

In a closely-watched decision, the FDA broadened the label for Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy to patients ages 4 and older. The approval goes beyond the patient population in which the…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

ADVERTISEMENT — Advertise With Biotech Networks